Valuation Gilead Sciences, Inc.

Stocks

Market Closed - Nasdaq Other stock markets 06:00:00 25/07/26 am AEST			5-day change	1st Jan Change
129.31 ^USD	-1.18%		-3.70%	+5.35%

24/07	Gilead Sciences, Inc. Recommends Trodelvy Plus Keytruda In PD-(L)1-Positive First-Line Metastatic Triple-Negative Breast Cancer	CI
24/07	Gilead Sciences Says EMA Recommends Trodelvy-Keytruda Combination for Breast Cancer	MT

Data adjusted to current consolidation scope

Fiscal Period: December	2021	2022	2023	2024	2025	2026	2027	2028
Market Cap ¹	91,081	107,677	100,942	115,118	152,281	160,547	-	-
Change	-	18.22%	-6.25%	14.04%	32.28%	5.43%	-	-
Enterprise Value (EV) ¹	118,530	126,522	118,665	131,838	169,585	170,145	160,547	150,592
Change	-	6.74%	-6.21%	11.1%	28.63%	0.33%	-5.64%	-6.2%
P/E	14.7x	23.6x	18x	243x	18.1x	-46.6x	16.4x	15.1x
PBR	4.32x	5.05x	4.48x	5.98x	6.73x	8.17x	6.38x	5.15x
PEG	-	-0.9x	0.8x	-2.7x	0x	0x	-0x	1.68x
Capitalization / Revenue	3.34x	3.95x	3.72x	4x	5.17x	5.28x	4.97x	4.71x
EV / Revenue	4.34x	4.64x	4.38x	4.59x	5.76x	5.59x	4.97x	4.42x
EV / EBITDA	8.12x	8.86x	9.01x	11.7x	10.6x	30.9x	8.94x	8.38x
EV / EBIT	9.45x	10.4x	11.3x	15.5x	12.9x	61.6x	10.3x	9.01x
EV / FCF	11x	15.2x	16x	12.8x	17.9x	211x	12.1x	10.7x
FCF Yield	9.12%	6.59%	6.25%	7.82%	5.58%	0.47%	8.24%	9.3%
Dividend per Share ²	2.84	2.92	3	3.08	3.16	3.296	3.409	3.102
Rate of return	3.91%	3.4%	3.7%	3.33%	2.57%	2.55%	2.64%	2.4%
EPS ²	4.93	3.64	4.5	0.38	6.78	-2.776	7.879	8.587
Distribution rate	57.6%	80.2%	66.7%	811%	46.6%	-119%	43.3%	36.1%
Net sales ¹	27,305	27,281	27,116	28,754	29,443	30,422	32,283	34,074
EBITDA ¹	14,598	14,283	13,177	11,287	15,953	5,510	17,953	17,972
EBIT ¹	12,548	12,180	10,484	8,520	13,193	2,763	15,576	16,718
Net income ¹	6,225	4,592	5,665	480	8,510	-3,391	9,762	10,457
Net Debt ¹	27,449	18,845	17,723	16,720	17,304	9,597	-	-9,955
Reference price ²	72.61	85.85	81.01	92.37	122.74	129.31	129.31	129.31
Nbr of stocks (in thousands)	1,254,384	1,254,244	1,246,042	1,246,266	1,240,680	1,241,570	-	-
Announcement Date	1/2/22	2/2/23	6/2/24	11/2/25	10/2/26	-	-	-

¹USD in Million²USD

Estimates

Add to a list 0 selected To use this feature you must be a member Log in Sign up	P/E (N)	EV / Sales (N)	EV / EBITDA (N)	Dividend Yield (N)	Capi.($)
GILEAD SCIENCES, INC.	-46.58x	5.59x	30.88x	2.55%	161B
ELI LILLY AND COMPANY	35.93x	12.68x	26.75x	0.57%	1,067B
JOHNSON & JOHNSON	28.24x	6.45x	17.87x	2.04%	635B
ABBVIE INC.	33.87x	7.65x	15.73x	2.65%	458B
ROCHE HOLDING AG	19.22x	4.69x	11.59x	2.82%	347B
NOVARTIS AG	21.56x	5.71x	14.24x	2.81%	295B
ASTRAZENECA PLC	21.1x	4.45x	12.31x	1.98%	262B
NOVO NORDISK A/S	14.14x	5.26x	10.84x	3.54%	216B
AMGEN INC.	24.66x	6.48x	11.43x	2.68%	203B
PFIZER INC.	12.46x	3.06x	7.75x	7.02%	140B
Average	16.46x	6.20x	15.94x	2.86%	378.34B
Weighted average by Cap.	24.49x	7.77x	18.30x	2.15%